Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
Provided By GlobeNewswire
Last update: Aug 7, 2025
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Read more at globenewswire.com
